Investigation of potential biomarkers associated with relapse in cervical cancer: miRNA-320a-3p and miRNA-136-5p
Strahlentherapie und Onkologie · 2025
DOI: 10.1007/s00066-025-02476-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, 2025. Verfasst von Melike Pekyürek Varan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey. melikepekyurek@gmail.com. Hauptthemen laut MEDLINE: MicroRNAs, Uterine Cervical Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Scientific Research Project Unit of the University of Health Sciences.
Abstract (Originalsprache)
PURPOSE: Micro ribonucleic acids (miRNAs) are short non-coding RNA molecules that control the expression of target mRNAs. Many miRNAs are dysregulated in various cancers, acting as tumor suppressors or oncogenes. This study aims to investigate the regulatory status of miRNA-320a-3p and miRNA-136-5p in cervical cancer development as well as their predictive significance for treatment response and disease recurrence. MATERIALS AND METHODS: Included in the study were 51 cervical cancer patients and 19 healthy controls. Expression levels of miRNA-320a-3p and miRNA-136-5p were detected using miRNA-specific quantitative real-time polymerase chain reaction (PCR). The relative expression of miRNAs was calculated using the 2-∆∆Ct method. RESULTS: miRNA-136-5p was downregulated in the cervical cancer patients compared to the controls (fold change: -3.06, p = 0.000239). In the case group, upregulation of miRNA-320a-3p was significantly associated with a poor treatment response (fold change: 1.88, p = 0.0264). Additionally, higher expression of miRNA-320a-3p was observed in patients with locoregionally confined recurrence both in the evaluation based on initial recurrence patterns (fold change: 1.38, p = 0.0341) and at last follow-up (fold change: 2.56, p = 0.000582). CONCLUSION: miRNA-136-5p can be proposed as a biomarker in cervical tumorigenesis, while miRNA-320a-3p can be used for treatment response and locoregional recurrence prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey. melikepekyurek@gmail.com.
- Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, Istanbul, Turkey.
- Department of Medical Biology, Hamidiye School of Medicine, University of Health Sciences, Istanbul, Turkey.
- Department of Radiation Oncology, Haydarpaşa Numune Training and Research Hospital, Istanbul, Turkey.
- Department of Radiation Oncology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.
- Department of Medical Pathology, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.
ORCID-Profile: Melike Pekyürek Varan, Gökhan Yaprak, Kübra Gündüz, Özlem Yetmen Doğan, Makbule Eren, Mervenur Şahin, Ender M Coşkunpınar
Förderung
- Scientific Research Project Unit of the University of Health Sciences
Zitieren
APA
Pekyürek Varan, M., Yaprak, G., Gündüz, K., Yetmen Doğan, Ö., Eren, M., Şahin, M., & Coşkunpınar, E. M. (2025). Investigation of potential biomarkers associated with relapse in cervical cancer: miRNA-320a-3p and miRNA-136-5p. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-025-02476-y
Vancouver
Pekyürek Varan M, Yaprak G, Gündüz K, Yetmen Doğan Ö, Eren M, Şahin M, et al. Investigation of potential biomarkers associated with relapse in cervical cancer: miRNA-320a-3p and miRNA-136-5p. Strahlentherapie und Onkologie. 2025. doi:10.1007/s00066-025-02476-y
BibTeX
@article{PekyrekVaran2025,
author = {Pekyürek Varan, Melike and Yaprak, Gökhan and Gündüz, Kübra and Yetmen Doğan, Özlem and Eren, Makbule and Şahin, Mervenur and Coşkunpınar, Ender M},
title = {Investigation of potential biomarkers associated with relapse in cervical cancer: miRNA-320a-3p and miRNA-136-5p},
journal = {Strahlentherapie und Onkologie},
year = {2025},
doi = {10.1007/s00066-025-02476-y}
}
EUVIMED